argenx stock after-hours at EUR 843.00: minus 1.74 percent versus prior close
Published on 09/30/2026 at 18:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
argenx stock was at EUR 843.00 after-hours at 6:50 p.m. CEST on September 30, 2026, down 1.74 percent versus the prior close of EUR 857.90 at Lang & Schwarz.
Trading session
The Lang & Schwarz quote showed a bid of EUR 841.80 and an ask of EUR 844.20. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of argenx stock.
New VYVGART data presented
argenx SE said on September 29 that it would present clinical, long-term and real-world data at the AANEM Annual Meeting and the MGFA Scientific Session in Orlando from September 29 through October 2. The presentations cover VYVGART and VYVGART Hytrulo in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, as well as empasiprubart and adimanebart. argenx identified the release date and the company as the issuer.
The company reported that Phase 3 ADAPT OCULUS data showed further improvement in mean patient-reported ocular scores after two additional VYVGART cycles. One-year ADAPT SERON results showed mean MG-ADL improvements of approximately 5 points maintained through Week 52 in patients without detectable anti-AChR antibodies. A real-world analysis of more than 1,100 U.S. MG patients reported a mean MG-ADL reduction of 4.7 points for patients treated within one year of diagnosis, compared with 3.5 points for those treated more than three years after diagnosis. GlobeNewswire published the announcement as a release from argenx SE.
